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Liquid liquids are attractive as carriers, and encapsulation and delivery systems for poorly water 
soluble/lipophilic compounds, e.g. for application as functional foods, vitamin supplements and pharmaceuticals. 
However, such lipid carriers are challenging to formulate as solid material products and are generally 
manufactured as soft gelatin capsules. These capsules require specific engineering facilities for manufacture, 
and in many cases do not have optimal stability/shelf life and cannot control the bioactivity or delivery properties.  
 
We have developed an alternative approach to encapsulate liquid lipids, i.e. by entrapment within a porous 
matrix structured microparticle, established through the assembly of inorganic or polymeric nanoparticles [1,2]. 
More specifically, these are prepared by drying (e.g. spray or freeze drying) a sub-micron lipid emulsion in the 
presence of inorganic (e.g. silica) or polymeric (e.g. PLGA) nanoparticles – see Fig. 1. 
     
 
 
We demonstrate that the porous nanostructure and surface chemistry of SLH and PLH particles controls their 
lipid/drug loading and biological activity, which in turn controls delivery performance. These encapsulation 
systems have potential for smart pharmaceutical delivery through various routes, e.g. oral, injectable and 
inhalation. Significantly, when considering oral delivery, improved bioavailability and other pharmacokinetic 
properties have been demonstrated for a number of poorly soluble drugs through in vivo studies on rodents, 
dogs and human clinical trials [3]. 
 
SLH and PLH particles are emerging as effective encapsulation systems for lipids and for enhancing the 
delivery of drugs via a smart interplay between the lipid-nanoparticle interaction and the action of lipid-digesting 
enzymes, which controls drug release, solubilization and absorption.  Mechanistic understanding of the 
biological performance of these particles is enabling the effective engineering of optimized carrier particles for 
drugs, vitamins and functional foods and can accelerate their development for translation into commercial 
products. 
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Figure 1 – Silica lipid hybrid (SLH) ((Stober silica (left) and fumed silica (centre)) and polymeric nanoparticle lipid 
hybrid (PLH) (right) particles as encapsulation and delivery systems for liquid lipids and lipophilic agents  
